CHENGDU, China, June 28 /PRNewswire-Asia/ -- Tianyin Pharmaceutical (NYSE Amex: TPI), a biopharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine and branded generics will exhibit and promote its flagship product portfolio at the 45th 2010 National New Special Drugs Trade Fair at Beijing National Convention Center from July 8th, till July 10th. Tianyin's portfolio is featured by the patented Ginkgo Mihuan Oral Liquid (GMOL) for cardiovascular and central nervous system indications, Apu Shuangxin (APU, Benorylate Granules) for fever, inflammation and rheumatism, Xuelian Chongcao Oral Solution (XLCC) for heart diseases, asthma and gynecological conditions, along with other prescription medicines that target high incidence China health care indications.
"Years of sales and marketing efforts by Tianyin Pharmaceutical have established a nationwide network that covers more than 850 hospitals with an in-depth market penetration," said Dr. Jiang, Guoqing. "The network synergizes with our marketing strategies that target high incidence, chronic conditions in a growing aging Chinese population whose health care spending is boosted by an increasing disposable income and health care funding by the government. This synergy is centered on our flagship portfolio such as GMOL, APU, and XLCC etc. that contributes close to 50% of our annual revenue."
About National New Special Drugs Trade Fair
http://www.newdrugschina.com/
The 45th National New Special Drugs Trade Fair gathers the leading pharmaceutical enterprises, elite new drug R&D institutes, the technology transfer organizations, and the biomedical science and technology industrial areas in China to offer a platform for both scientific and commercial collaboration and development. An International new medicine technology transfer and the commercialization collaboration summit will be conducted with the main Trade Fair.
About Tianyin Pharmaceutical
Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that specializes in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics. Tianyin is equipped with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, of which 23 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please contact:
Tianyin Pharmaceutical Co., Inc.
James Jiayuan Tong M.D. Ph.D.
Chief Financial Officer, Chief Business & Development Officer
Director
23rd Floor Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China
Web: http://www.tianyinpharma.com
Email: Dr.Tong@tianyinpharma.com
Tel: +86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011
+1-949-350-6999 (U.S.)
